PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523781-25-00

Enrollment

Registered

2026-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

localized or locally advanced renal cell cancer (RCC), metastatic solid cancer, muscle invasive bladder cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Feb 4, 2026